Dr. Coffman on Safety Concerns With PARP Inhibitors in Ovarian Cancer

Video

In Partnership With:

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

One of the main concerns of combining cytotoxic chemotherapy with PARP inhibitors as frontline maintenance therapy is the potential for increased myelosuppression, says Coffman. If patients cannot tolerate chemotherapy due to the increase in myelosuppression, they could be deprived of an overall survival benefit.

Additionally, there is concern that the combination could increase the risk of leukemic transformation as a result of increased DNA damage. However, further research is being done to see whether these concerns outweigh the potential benefits of treatment, concludes Coffman.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,